Effect of the Dual Glucose‐Dependent Insulinotropic Peptide/Gulcagon‐like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta‐analysis.

Plain-language guide to PMID 37455226 (2023): meta-analysis of Tirzepatide and GIP (Gastric Inhibitory Polypeptide).

Key Facts

PMID: 37455226
Journal: Clinical therapeutics
Year: 2023
Study type: Meta-Analysis
Authors: Yu D et al. (4 authors)
DOI: 10.1016/j.clinthera.2023.06.008

What This Paper Covers, in Plain Language

What It Covers

This meta-analysis looks at Tirzepatide and GIP (Gastric Inhibitory Polypeptide).

Tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide 1 receptor agonist, has been approved by the US Food and Drug Administration for the treatment of type 2 diabetes.

The purpose of this meta-analysis is to evaluate the impact of tirzepatide on lipid profile and waist circumference (WC), both of which are risk factors of cardiovascular diseases.

The Cochrane risk-of-bias tool for randomized trials, version 2 was used to assess the outcome's risk of bias.

Who the Included Studies Covered

The researchers evaluated the evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system.

How the Review Was Done

The PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov databases were systematically searched for articles published from database inception to July 31, 2022.

This meta-analysis included 7 randomized controlled trials with a minimum duration of 12 weeks that compared tirzepatide with placebo or other antidiabetic medications.

The random-effects model was used to estimate mean differences in lipid profile and WC from baseline.

What Was Measured

PubMed files the paper under topics including Gastric Inhibitory Polypeptide, Diabetes Mellitus, Type 2, Waist Circumference, Peptides, Hypoglycemic Agents, Lipids and Glucagon-Like Peptide-1 Receptor.

The authors tagged it with the keywords Cardiovascular diseases, Dual GIP/GLP-1 receptor agonist, Lipid profile, Meta-analysis and Tirzepatide.

What This Means in Plain Language

This is a meta-analysis of Tirzepatide and GIP (Gastric Inhibitory Polypeptide).

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Clinical therapeutics), a journal based in United States.

More context: the Tirzepatide compound page and the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.

Our Notes on the Compounds

Tirzepatide: A prescription peptide medicine that acts on both the GIP and GLP-1 receptors; Mounjaro and Zepbound contain the same active ingredient.

GIP (Gastric Inhibitory Polypeptide): A 42-amino-acid gut hormone that boosts insulin release after meals; one of the two receptors tirzepatide acts on.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.